Rubicon global launch status and price overview

Lurbinectedin (Lurbinectedin), this high-profile innovative drug, has been successfully launched in many countries and regions around the world and has begun to be widely used in clinical applications. After a series of rigorous scientific research and clinical trials, rubicatin has demonstrated excellent efficacy and safety in the treatment of metastatic small cell lung cancer that has progressed after platinum-based chemotherapy.

On June 15, 2020, the U.S. Food and Drug Administration (FDA) officially approved the marketing application for rubicatin, marking an important breakthrough for this drug in the treatment of small cell lung cancer. Since then, Rubicatin has been approved for marketing in many countries, demonstrating the widespread recognition of its efficacy by the international medical community. At the same time, the drug has also been included in multiple authoritative cancer treatment guidelines, including the ESMO Small Cell Lung Cancer Guidelines and the NCCN Small Cell Lung Cancer Guidelines, further consolidating its leading position in the field of lung cancer treatment.

Although Rubicatin is not currently on the market in mainland China, domestic patients still have the opportunity to purchase this drug through foreign channels or consult professional overseas medical service institutions to obtain this drug. The Rubicatin currently available on the market is the original version, produced by the Spanish biopharmaceutical company PharmaMar. This version is available in Singapore and the United States in 4 mg per box. In the United States, the drug is priced at 91,000 yuan per box, while in Singapore, the price is more affordable at only 34,000 yuan per box.

For more questions or needs about Rubicatin, patients are recommended to consult regular overseas medical consulting companies to obtain professional and accurate information and services. Overall, rubicatin, as a new anti-cancer drug, has been successfully launched and widely used around the world, providing patients with small cell lung cancer with a new treatment option and bringing them more survival opportunities and hope.